Short Interest in Innovent Biologics, Inc. (OTCMKTS:IVBXF) Increases By 5.4%

Innovent Biologics, Inc. (OTCMKTS:IVBXFGet Rating) was the target of a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 6,375,300 shares, an increase of 5.4% from the January 31st total of 6,048,300 shares. Based on an average daily trading volume, of 2,100 shares, the days-to-cover ratio is currently 3,035.9 days.

Innovent Biologics Stock Performance

Shares of OTCMKTS IVBXF opened at $4.77 on Tuesday. Innovent Biologics has a twelve month low of $2.29 and a twelve month high of $6.00. The business has a 50 day simple moving average of $5.06 and a 200-day simple moving average of $4.29.

Innovent Biologics Company Profile

(Get Rating)

Innovent Biologics, Inc operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma.

Featured Stories

Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with's FREE daily email newsletter.